Stoke Therapeutics to Present STK-002 Data at AAO 2026 Meeting

Stoke Therapeutics announced that data for its investigational medicine STK-002, intended for the treatment of Autosomal Dominant Optic Atrophy (ADOA), will be presented at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting.